We evaluated immune reconstitution in 58 adults who received hematopoietic SCTs from allogeneic siblings (allosib), matched unrelated donors (MUD) or cord blood (CB) at 90-day intervals for 1 year post transplant. CB recipients had a higher incidence of infections in the first 100 days compared with allosib and MUD recipients. The number of circulating T cells was lower in CB recipients compared with MUD recipients at 90 days and compared with allosib recipients at 180 days. Spectratype analysis of the TCR Vb complementarity determining region 3 (CDR3) of patient lymphocytes revealed that the TCR repertoire remained poorly diversified even at 360 days in nearly all patients. In contrast, the number of circulating B cells was significantly elevated in CB recipients compared with allosib recipients throughout the first year post transplant and compared with MUD recipients at 9-12 months. Spectratype analysis of the B-cell receptor V H CDR3 showed that the B-cell repertoire was diversified in most patients by 90 days. CD5 pos B cells from assayed CB recipients expressed intracellular IL-10 early post transplant. Our data suggest that B cells, in addition to T cells, may have a role in impaired immune responses in CB transplant patients.
INTRODUCTION
Hematopoietic SCT (HSCT) is an option for leukemia patients who cannot achieve long-term remission with chemotherapy. Cord blood (CB) was first used as an alternative to BM as a source of HSCs in pediatric patients due to the low number of HSCs in CB compared with BM. 1 Recently, the number of adults receiving CB transplants (CBTs) has been increasing due to advances in the expansion of CB HSCs and an increase in the availability of CB units collected from ethnic minorities. Advantages of using CB as a source of HSCs include a low prevalence of latent viral disease 2 and low incidence of GVHD in CBT recipients compared with BMT recipients. [3] [4] [5] However, there are significant disadvantages to CBT including delayed hematopoietic recovery [4] [5] [6] [7] [8] [9] and a higher incidence of life-threatening infections especially in the first 100 days post transplant [10] [11] [12] compared with BM recipients. Taken together, these data suggest that immune responses are impaired in CBT patients especially in the first few months post transplant.
To identify strategies for improving the success of adult CBT, we compared the incidence of infection and GVHD as well as survival and immune reconstitution in adult transplant patients receiving stem cells from allogeneic siblings (allosib), matched unrelated donors (MUD) or CB. As T-cell numbers are low and the TCR repertoire is not well diversified 1 year or longer after HSCT in both BM recipients [13] [14] [15] and CB recipients, 16, 17 we hypothesized that immune cells, other than T cells, contribute to impaired immune responses in CBT patients. To address this hypothesis, we quantified multiple T-cell subsets, B cells, monocytes and granulocytes in peripheral blood from CB, allosib and MUD recipients at 90-day intervals for 1 year post transplant. In addition, we performed spectratype analysis to assess the genetic variation in complementarity determining region 3 (CDR3), the third hypervariable region, of the TCR b chain (Vb) and the BCR heavy chain (V H ) in fresh CB and patient peripheral blood lymphocytes.
MATERIALS AND METHODS Patients
A total of 22 allosib, 17 MUD and 19 CBT patients of both sexes and various ethnicities aged 25-67 years were enrolled in this study. Informed consent was obtained from all patients in accordance with the Helsinki Declaration. All procedures were approved by Loyola University Chicago's Institutional Review Board. Preparative regimens were myeloablative in all but two transplant patients with TBI and regimens including one or more of the following: BU; cytarabine; CY; fludarabine; melphalan; pentostatin; BEAM. Single-agent tacrolimus (FK-506) was given for 100 days post transplant and then tapered in all patients. All but one allosib patient received mobilized peripheral blood stem cells (PBSC); the remaining allosib received BM from an HLA-mismatched sibling. A total of 11 MUD recipients received BM and 6 received PBSC. Keratinocyte growth factor was given to 38 patients to reduce mucositis. Anti-thymocyte globulin was given to seven patients (two allosib and five CB) as part of their preparative regimen. Peripheral blood was collected from patients undergoing HSCT every 90 days for 1 year post transplant. One allosib that received a nonmyeloablative regimen was given DLI at 6 months to improve chimerism. Relapsed patients were not evaluated beyond the date of relapse. (Coralville, IA, USA) . PCR products were loaded on to an ABI PRISM 3130 genetic analyzer (Applied Biosystems, Carlsbad, CA, USA) and histograms of CDR3 lengths for each of the Vb and V H families were generated using the GeneMapper 4.1 software (Applied Biosystems, Carlsbad, CA, USA). A diversity score was assigned to each family as follows: 0, no peak; 1, one peak; 2, two to seven peaks; 3, eight or more peaks with non-Gaussian distribution; 4, eight or more peaks, Gaussian distribution. Representative profiles are shown in Figure 3a . We defined a Gaussian distribution as eight or more consecutive peaks that were no more than three nucleotides apart.
Determination of GVHD and infection
Enumeration of leukocyte populations PBMC were stained with the following antibodies from eBioscience (San Diego, CA, USA), Invitrogen, Biolegend (San Diego, CA, USA) or Becton Dickinson (BD) Pharmingen (Franklin Lakes, NJ, USA): CD19 (AF750 or FITC), CD38 (PECy5), immunoglobulin (Ig)M (APC), IgD (phycoerythrin (PE)), CD3 (FITC or APC), CD4 (APC-Cy7 or PE), CD8 (PECy7), CD56 (PE), TCRab(FITC), TCRgd(PE), CD14 (FITC), CD25 (PE), CD127 (PECy5) and CD5 (FITC). Cells were analyzed on a FACs Canto or FACs Canto II (BD) and flow cytometry data were analyzed using the FlowJo software (Treestar, Ashland, OR, USA).
Statistics
Statistical analyses were performed using the GraphPad Prism software version 4 (GraphPad software, La Jolla, CA, USA).
RESULTS

Patient Characteristics
The main patient characteristics are summarized in Table 1 . Most allosib and MUD recipients were matched at both alleles for the HLA A, B, C and DR. In addition, MUD patients were matched at both alleles for HLA-DQ. Most CB recipients were antigen mismatched for HLA-A and/or HLA-B but were all matched for both alleles of HLA-DR. BMT recipients received more total nucleated cells and CD34 pos cells compared with CBT recipients (Table 2 ). Three CBT patients were enrolled in a clinical trial sponsored by Gamida Cell Ltd (Jerusalem, Israel); 1 day after stem cell infusion, these patients received cells that had been thawed from a fraction of their CB unit and expanded in vitro for 21 days. As their immune recovery and outcomes were similar to CB recipients that did not receive expanded cells, they were included in the analyses.
Engraftment and chimerism Neutrophil engraftment was defined as the first of 3 consecutive days after HSCT when the ANC was at least 500 cells/mL. Neutrophil engraftment was more rapid in PBSC recipients compared with BM and CB recipients ( Table 2 ). Platelet engraftment was defined as the time to reach a sustained platelet count of at least 20 000/ mL without the use of transfusions. Platelet engraftment was significantly delayed in CB recipients compared with BM or PBSC recipients (Table 2) . Donor-recipient chimerism was determined by PCR analysis on whole blood for STR sequences, and results were expressed as Immune reconstitution after SCT BC Beaudette-Zlatanova et al percentage donor-derived DNA. By 3 months, all but one CBT recipient achieved 98% donor chimerism; this patient had 92% donor chimerism at 90 days but relapsed and was excluded from further study. Two allosib patients that did not achieve 98% chimerism until 5 months or 7 months post transplant expired within the first year; one died following a myocardial infarction that was not treatment-related and one died due to sepsis and GVHD.
Post-transplant complications Several patients relapsed or succumbed to infection in the first year post transplant. The percentage of patients alive at 1 year was similar for patients receiving stem cells from different donor sources (allosib (92%), MUD (95%), CB (63%); Kaplan-Meier survival analysis, P40.05, data not shown). The incidence of aGVHD and cGVHD was similar between CBT patients and allosib and MUD patients (w 2 ¼ 0.5451, P40.05, d.f. ¼ 1, w 2 test; P40.05, Fisher's exact test). However, the severity of cGVHD differed between patient groups. The disease was severe in only 3 of 13 CBT patients whereas the disease was severe in more than half of the 29 allosib and MUD patients (Table 3) . Of note, all five of the MUD PBSC recipients that could be evaluated for cGVHD developed severe cGVHD.
As it has been reported that CBT recipients have a higher incidence of infections compared with BMT recipients during the first 100 days post transplant, 4, 12, 18 we determined the number of bacterial, viral and fungal infections that our patient population acquired during this time period (Table 3) . Only infections that were confirmed by laboratory tests were included except for one incident of varicella zoster infection, which was based on the symptoms presented by the patient. HSCT patients acquired infections that were primarily caused by bacteria or by viruses that were reactivated in the lymphopenic hosts. Two CBT patients, one allosib patient and two MUD transplant patients acquired multiple infections. CBT patients had a higher risk of developing opportunistic infections in the early post-transplant period compared with allosib and MUD recipients (P ¼ 0.02, Fisher's exact test). All patients survived 100 days post transplant, however, several succumbed to infections within the first year. One MUD recipient became infected with Stenotrophomonas maltophilia and had oral candidiasis within the first 100 days post transplant and expired at 5 months from sepsis. Another MUD recipient and two allosib recipients died of pneumonia caused by an unidentified organism within the first year. One CBT patient died of fungal pneumonia subsequent to infection with Klebsiella pneumoniae in the first 100 days. Three other CBT patients, one with sepsis, one with viral pneumonia and one with pneumonia caused by Pseudomonas aeruginosa expired in the first year. We hypothesized that CBT patients are more susceptible to infection and experience less severe GVHD because immune reconstitution in these patients differs from reconstitution in patients receiving HSCs from other sources.
Influence of graft source and donor source on lymphocyte reconstitution Previous studies have shown differences in immune reconstitution between patients receiving BM cells and patients receiving PBSC. 19, 20 To explore the influence of graft source on immune reconstitution, we enumerated multiple T-cell subsets and B cells in the peripheral blood of 6 MUD BM and 11 MUD PBSC recipients. In our study, we were unable to compare graft source in allosib recipients as all but one of 22 allosib patients received PBSC. MUD PBSC recipients had significantly more CD4 T cells at 90 days than MUD BM recipients (P ¼ 0.04, Mann-Whitney test, data not shown). Seven allosib or MUD and three CB recipients that expired or relapsed before the development of chronic GVHD could be assessed were excluded from the analysis.
Immune
Post-transplant outcomes differ between adult BMT and adult CBT patients; 4, 7, 8, 12 therefore, we examined whether donor source influences immune reconstitution. The number of CD4 T and CD8 T cells was significantly higher in MUD recipients compared with CB recipients at 90 days. However, the median number of CD4 T and CD8 T cells was below normal in all patient groups as long as 1 year post transplant except for allosib patients at 180 days when the median CD8 T-cell count was at the low end of the normal physiological range (Figure 1a, b) . CD4 T cell and CD8 T-cell counts at day 180 were higher in patients receiving allosib cells compared with patients receiving MUD or CB cells (Figure 1a, b) . A comparison of CD4 T and CD8 T-cell count in 21 allosib PBSC recipients and 11 MUD PBSC recipients revealed that allosib PBSC recipients had more circulating CD4 T and CD8 T cells than MUD PBSC recipients (Po0.05, Mann-Whitney test, data not shown). By 360 days post transplant, the number of CD4 T cells was similar between allosib and CB recipients, however CB recipients had significantly more CD4 T cells than MUD recipients (Figure 1a 
Diversity of the lymphocyte repertoire in HSCT patients
We hypothesized that immune competence in CBT patients may be compromised by a restricted lymphocyte repertoire. To determine whether or not CB-derived cells were capable of giving rise to a diversified T-and B-cell repertoire, we analyzed the CDR3 region of each of 6 BCR V H and 11 TCR Vb gene families (representative profiles are shown in Figure 3a) in PBMC from fresh CB samples. In all, 6 of the 10 samples analyzed had a welldiversified BCR repertoire and 8 of the 10 samples had a welldiversified TCR repertoire (Figure 3b) . We then analyzed the lymphocyte repertoire of HSCT patients. The majority of B cells from CBT recipients displayed a diversified repertoire as early as 90 days and remained diversified as long as 360 days post transplant (Figure 4a) . B cells from four of seven allosib or MUD recipients displayed a diversified repertoire at 90 days; however, the repertoire became more restricted in some patients by 270 days post transplant (Figure 4a ). In contrast, the TCR repertoire was poorly diversified in most HSCT recipients as long as 360 days post transplant (Figure 4b) . We compared Vb and V H usage in CBT and allosib or MUD recipients and found that Vb usage was similar in both patient groups (Figure 4c 
(13) (13) 180 days (16) Figure 5 ). IL-10-producing B cells were not observed in the circulation of these patients at day 270 or at day 360 (data not shown). These data suggest that IL-10-producing peripheral B cells are present in the first 6 months post transplant but do not persist.
Myeloid reconstitution in HSCT patients
Myeloid recovery as measured by the time to neutrophil engraftment is delayed in CBT recipients compared with BMT recipients. [3] [4] [5] We determined whether the number of monocytes and granulocytes in HSCT recipients was different among patients receiving HSCs from different sources. Our data show that the number of monocytes was significantly higher in CBT patients compared with allosib patients at all time points. CBT patients had more circulating monocytes than MUD recipients at 90 days and at 180 days, but the numbers were similar in both groups at later time points. The number of monocytes was supraphysiological in some patients throughout the first year post transplant (Figure 6a ). Granulocytes were elevated in CBT patients in the first 6 months post transplant but were comparable to allosib and MUD patients thereafter (Figure 6b ).
DISCUSSION
Infection, predominantly caused by bacteria, is the primary cause of death in 15-47% of CBT patients. 6, 12, 23 Although many studies have attributed infection in CBT patients to low T-cell numbers and a restricted TCR repertoire, 16, 24, 25 our data show that T-cell numbers are below the normal physiological range and that the (11) (11) (12) 360 days (14) There is limited data on B-cell reconstitution in HSCT patients. Some studies have reported that the BCR repertoire is fully diversified as early as 3 months post transplant, 26, 27 whereas other studies report that diversification does not occur until 9-12 months post transplant. 28, 29 Though B-cell numbers were lower in allosib and MUD recipients compared with CB recipients, the BCR repertoire was well diversified in all patient groups as early as 90 days post transplant. The higher number of B cells observed in CBT patients was not due to oligoclonal expansion as the BCR repertoire was not skewed in these patients. CBT patients in this study show an increase in the number of circulating B cells even after T-cell numbers are equivalent to those observed in allosib and MUD patients. These data suggest that elevated B-cell numbers in CBT recipients are not the result of compensatory expansion but the result of increased B-cell lymphopoiesis or survival. Our data show that monocytes are more abundant in CBT recipients than allosib recipients throughout the first year post transplant. B-cell activating factor produced by activated monocytes has been shown to promote the survival of peripheral B cells 30, 31 and to protect leukemic B cells from apoptosis. 32, 33 A recent study has shown that patients receiving a double CBT have elevated B-cell numbers and elevated plasma levels of B-cell activating factor in the early post-transplant period compared with MUD recipients. 34 B-cell activating factor . CDR3 spectratype analysis of peripheral blood lymphocytes from patients that underwent HSC transplantation. CDR3 spectratype analysis of the BCR repertoire (a) and TCR repertoire (b) from CBT recipients (left panels) and from patients receiving stem cells from an allosib or MUD (right panels). A complexity score was calculated by summing the individual diversity scores for each BCR or TCR family. The BCR repertoire was considered well-diversified if the complexity score was X18 (score of at least 3 for all 6 V H families), and the TCR repertoire was considered well-diversified if the complexity score was X33 (score of at least 3 for all 11 production by monocytes was not evaluated. Therefore, further study is required to determine whether monocytes contribute to elevated B-cell numbers or contribute to relapse in CBT patients.
We hypothesize that B cells may attenuate T-cell responses in CBT patients. B-cell recovery has been correlated with an improvement in cGVHD; 35, 36 patients with cGVHD have decreased numbers of B-cell precursors even in the absence of steroid treatment. 36 The incidence of cGVHD was similar in all HSCT recipients; however, the incidence of severe cGVHD was low in CB recipients. IgM pos IgD pos CD38 pos CD5 pos B cells are in circulation in both CBT recipients and BMT recipients in the first few months post transplant. 37, 38 In BMT patients, CD5 pos B cells are thought to represent a transitional B-cell population and the percentage of CD5 pos B cells decreases as the number of mature B cells increases. 39 We analyzed CD5 pos B cells from three CBT recipients for the expression of CD24 (also known as heat stable antigen), a molecule that is highly expressed by transitional B cells. 39 pos Breg that produce IL-10 have been described in mice. 22, 40 The phenotype of Breg cells in humans has yet to be fully elucidated; however, human B cells capable of suppressing T-cell responses have been described. 41, 42 CD5 pos B cells positive for intracellular IL-10 at 90 and 180 days were present in two patients receiving a reduced intensity conditioning regimen supporting the possibility that these cells are Breg. However, the IL-10 pos B cells were not present at 270 or 360 days in these two patients or in patients that received a myeloablative conditioning regimen. From these data, we cannot determine whether the number of IL-10 pos B cells declines over time or whether circulating IL-10 pos B cells are present only in reduced intensity conditioning patients. More patients must be analyzed to distinguish between these possibilities. Future studies characterizing the function of the CD5 pos B-cell population in CBT patients will determine whether or not this population of B cells is capable of producing cytokines 
